Intense Pulsed Light (IPL) Medical Device as Treatment for Patient Suffering From Skin Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEurofeedback
About this trial
The first IPL device obtained United States Food and Drug Administration (FDA) clearance in 1995 for treatment of lower extremity telangiectasias. Since then, its favorable cost and versatility in contrast to many singlespectrum lasers, has led to its rapid proliferation and use in a number of different clinical settings. As described in the literature, ANTHÉLIA medical device is intended to treat skin disorders:
* Excessive Hairiness (Hirsutism, Hypertrichosis...) * Vascular lesions (Rosacea….) * Pigmented lesions (Lentigo et melasma) * Acne vulgaris
Eligibility criteria
Qualifiers
Adult men or women
Patient with unwanted hair on the body (legs, arms, bikini line, or axilla)
Patient over 18 years.
Patients with Fitzpatrick skin types from I to V.
Disqualifiers
Patients with history of malignant lesions or pre-malignant lesions, scarring, or infection in the area to be treated History of keloidal or hypertrophic scarring
Patients with a known photosensitivity
Pregnancy women
Patient with diabetes mellitus suntan in the area to be treated
Trial design
Treatments tested in this trial
- intense pulsed light
Treatment groups
85 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov